Search results for Ibritumomab

Ibritumomab Biosimilar – Anti-MS4A1(CD20,MS4A-1) mAb – Research Grade, ProteoGenix, PX-TA1620

Description of Ibritumomab Biosimilar - Anti-MS4A1(CD20,MS4A-1) mAb - Research Grade Title: Understanding the Structure and Function of Ibritumomab Biosimilar – Anti-MS4A1(CD20,MS4A-1) mAb Introduction: Ibritumomab Biosimilar is a monoclonal antibody (mAb) that targets the protein MS4A1, also known as CD20, on the surface of B cells. It is a biosimilar of the original drug ibritumomab tiuxetan, which is used for the treatment of non-Hodgkin’s lymphoma. In this article, we will delve into the structure, activity, and potential applications of Ibritumomab Biosimilar as a research grade antibody. Structure of Ibritumomab Biosimilar: Ibritumomab Biosimilar is a recombinant, chimeric monoclonal antibody, meaning it is produced by combining genetic material from two different species – human and mouse. It consists of two heavy chains and two light chains, each with a specific amino acid sequence that determines its structure and function. The heavy chains are responsible for binding to the target protein, MS4A1, while the light chains provide support and stability to the antibody. Activity of Ibritumomab Biosimilar: As a monoclonal antibody, Ibritumomab Biosimilar specifically targets and binds to the protein MS4A1 on the surface of B cells. This binding triggers a series of events that ultimately leads to the destruction of the B cell. The antibody recruits immune cells, such as natural killer cells and macrophages, to the site of the bound B cell and activates them to attack and destroy the cell. This mechanism of action is known as antibody-dependent cell-mediated cytotoxicity (ADCC). Applications of Ibritumomab Biosimilar: Ibritumomab Biosimilar, as a research grade antibody, has several potential applications in the field of immunology and cancer research. Its primary use is in the study of B cell biology and the role of MS4A1 in B cell function. By targeting and depleting B cells, researchers can investigate the effects of B cell deficiency on the immune system. This can also aid in the development of new therapies for B cell-related diseases. Moreover, Ibritumomab Biosimilar can also be used in the development of new cancer treatments. The overexpression of MS4A1 has been observed in various types of B cell lymphomas, making it a potential therapeutic target. By targeting and destroying MS4A1-expressing B cells, Ibritumomab Biosimilar can potentially be used as a treatment for these types of cancers. In addition, Ibritumomab Biosimilar can also be used in diagnostic assays for B cell-related diseases. The specificity of the antibody for MS4A1 allows for the detection and quantification of B cells in patient samples. This can aid in the diagnosis and monitoring of diseases such as B cell lymphomas and autoimmune disorders. Conclusion: In conclusion, Ibritumomab Biosimilar is a chimeric monoclonal antibody that specifically targets the protein MS4A1 on B cells. Its structure and activity make it a valuable tool for studying B cell biology and the development of new cancer treatments. As a research grade antibody, it has the potential for various applications in the fields of immunology and cancer research. Further studies and developments in this area can lead to the advancement of new therapies and diagnostic tools for B cell-related diseases.

Ibritumomab, Abbexa, abx831581

Ibritumomab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MS4A1(CD20, MS4A-1), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ibritumomab is a monoclonal antibody directed against the CD20 antigen found on pre-B and mature B lymphocytes (normal and malignant). Ibritumomab binding induces apoptosis in B lymphocytes in vitro. It is combined with the chelator tiuxetan, which acts as a specific chelation site for Yttrium-90 (Y-90). The monoclonal antibody acts as a delivery system to direct the radioactive isotope to the targeted cells, however, binding has been observed in lymphoid cells throughout the body and in lymphoid nodules in organs such as the large and small intestines. Beta-emission induces cellular damage through the formation of free radicals (in both target cells and surrounding cells).

Ibritumomab ELISA Kit, ProteoGenix, KPTX177

Description of Ibritumomab ELISA Kit Introduction: Ibritumomab is a monoclonal antibody used in the treatment of non-Hodgkin’s lymphoma. It specifically targets the CD20 antigen, which is found on the surface of B-cells. This makes it an important therapeutic target in the treatment of B-cell malignancies. The Ibritumomab ELISA Kit is a reliable and sensitive tool used to detect and quantify the presence of this antibody in patient samples. In this article, we will discuss the structure, activity, and application of the Ibritumomab ELISA Kit. Structure of Ibritumomab: Ibritumomab is a chimeric monoclonal antibody, meaning it is a combination of mouse and human antibodies. It is composed of two heavy chains and two light chains, each with a specific amino acid sequence. The variable regions of the antibody, responsible for binding to the CD20 antigen, are derived from the mouse antibody. The constant regions, which determine the effector functions of the antibody, are derived from human antibodies. This unique structure allows for high specificity and affinity towards the CD20 antigen. Activity of Ibritumomab: The main activity of Ibritumomab is to bind to the CD20 antigen on B-cells, leading to their destruction. This is achieved through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. ADCC involves the recruitment of immune cells, such as natural killer cells, to the site of the bound antibody, resulting in the destruction of the target cell. CDC involves the activation of the complement system, leading to the formation of a membrane attack complex that causes cell lysis. Direct induction of apoptosis occurs when the bound antibody triggers programmed cell death in the target cell. Application of Ibritumomab ELISA Kit: The Ibritumomab ELISA Kit is a valuable tool in the diagnosis, monitoring, and research of non-Hodgkin’s lymphoma. It is used to detect and quantify the levels of Ibritumomab in patient samples, providing valuable information on the efficacy of treatment and potential relapse. The kit is also used in pharmacokinetic studies to determine the distribution, metabolism, and elimination of Ibritumomab in the body. In addition, the Ibritumomab ELISA Kit is used in research to study the expression and function of the CD20 antigen, as well as to develop new therapeutic strategies targeting this antigen. Specific Titles: 1. The Role of Antibodies in Cancer Treatment 2. Understanding the Structure of Ibritumomab 3. How Ibritumomab Targets B-cell Malignancies 4. The Mechanisms of Action of Ibritumomab 5. Advancements in Detection: The Ibritumomab ELISA Kit 6. Using the Ibritumomab ELISA Kit in Non-Hodgkin’s Lymphoma Diagnosis 7. Monitoring Treatment Efficacy with the Ibritumomab ELISA Kit 8. Studying CD20 Antigen Expression with the Ibritumomab ELISA Kit 9. Future Directions: The Potential of Ibritumomab in Cancer Research 10. The Importance of Specificity and Sensitivity in the Ibritumomab ELISA Kit.

Ibritumomab ELISA Kit, Abbexa, abx395066

Ibritumomab ELISA Kit is a quantitative ELISA kit for detection of Ibritumomab.

Ibritumomab Biosimilar - Research Grade, ichor.bio, ICH5310

Detects human CD20

Research Grade Ibritumomab (HY257036), abinScience, HY257036